Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Review

HER2-Targeted Therapy for Metastatic Colorectal Cancer: Current Evidence, Patient Selection, and Practical Treatment Sequencing

T. Sagawa H. Nagashima K. Fujikawa
Aug 2026 · Journal of Gastrointestinal Cancer · Vol 57 · 0 citations · 29 references
Medicine

TL;DR

This narrative review focuses on the practical integration of HER2 testing and HER2-directed treatment into mCRC care and proposes a clinician-oriented framework for early patient identification, treatment sequencing, and resistance assessment.

DOI PubMed Semantic Scholar
View source

Similar papers

Review Open access Sep 2026

HER2-Targeted Antibody-Drug Conjugates in Advanced HER2-Low Breast Cancer: Mechanisms, Clinical Efficacy, and Resistance Strategies

Abstract Globally, breast cancer is the most frequently diagnosed malignancy in women, with the HER2-low subtype (IHC 1+ or IHC 2+/ISH−) accounting for approximately 45%–55% of all invasive breast cancer cases. Conventional HER2-targeted therapies are ineffective for this subtype, and treatment has long relied on endoc...

Meng-Sha Yang, Xiao-Kun Ding, Peng Ye et al. · 0 citations
Review Sep 2026

Innovative Therapies for HER2-altered Non-Small Cell Lung Cancer: a Narrative Review.

A narrative review summarizes the clinicopathological features of HER2-altered NSCLC, critically evaluates emerging HER2-targeted therapies, and discusses future treatment directions.

Oscar Arrieta, E. Caballé-Pérez, L. Cabrera-Miranda et al. · 0 citations
Open access Sep 2026

HER2 amplification as a resistance mechanism to osimertinib and its successful treatment with trastuzumab deruxtecan: a case report

Acquired resistance to osimertinib in EGFR-mutant advanced non-small cell lung cancer is inevitable, and management following progression remains an evolving clinical challenge. HER2 amplification is a recognised but underreported off-target resistance mechanism, and its optimal management is not yet established. Tra...

Mansi Sharma, Ritwika Choudhury, Abhinav Dewan et al. · 0 citations
Review Sep 2026

Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.

INTRODUCTION Recently, both HER2 tyrosine kinase inhibitors (TKIs) and antibody drug conjugates (ADCs) targeting HER2 have demonstrated clinically meaningful activity and received regulatory approval for advanced HER2-mutant NSCLC, although evidence is primarily derived from single-arm trials with modest sample sizes a...

M. Li, Yu Yang Soon, Pui-Yin Au-Yeung et al. · 0 citations
Review Sep 2026

Biomarker-Guided Treatment Selection in Metastatic Colorectal Cancer: A Critical Review of Established and Emerging Therapies.

This structured narrative review separately examines mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) and microsatellite-stable/mismatch repair-proficient (MSS/pMMR) disease and distinguish established treatments from investigational strategies and identify the remaining evidence gaps.

Alireza Tojjari, Shamim Pourbahrighesmat, Shahd Alkhazna et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.